Vericel Co. (NASDAQ:VCEL) Director Steven C. Gilman Sells 5,833 Shares of Stock

Vericel Co. (NASDAQ:VCEL) Director Steven C. Gilman sold 5,833 shares of Vericel stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total value of $241,252.88. Following the transaction, the director now directly owns 11,000 shares in the company, valued at approximately $454,960. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vericel Price Performance

Shares of NASDAQ:VCEL opened at $41.66 on Friday. The stock has a market capitalization of $2.02 billion, a P/E ratio of -4,166.00 and a beta of 1.67. The business has a 50-day moving average of $45.26 and a two-hundred day moving average of $46.74. Vericel Co. has a fifty-two week low of $32.28 and a fifty-two week high of $54.10.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). The business had revenue of $52.70 million for the quarter, compared to the consensus estimate of $52.59 million. Vericel had a return on equity of 0.35% and a net margin of 0.37%. The firm’s revenue was up 14.8% compared to the same quarter last year. During the same period last year, the business earned ($0.11) EPS. As a group, research analysts expect that Vericel Co. will post 0.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VCEL has been the topic of a number of research analyst reports. StockNews.com downgraded shares of Vericel from a “hold” rating to a “sell” rating in a research report on Tuesday, October 8th. Canaccord Genuity Group assumed coverage on shares of Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price target on the stock. BTIG Research cut their price objective on Vericel from $56.00 to $55.00 and set a “buy” rating for the company in a report on Monday, July 15th. Canaccord Genuity Group started coverage on Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 target price on the stock. Finally, TD Cowen raised their price target on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.71.

Institutional Trading of Vericel

Large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Vericel by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 3,374,093 shares of the biotechnology company’s stock worth $120,151,000 after acquiring an additional 48,514 shares during the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Vericel by 2.5% in the first quarter. Los Angeles Capital Management LLC now owns 27,367 shares of the biotechnology company’s stock worth $1,424,000 after purchasing an additional 673 shares during the period. Park Avenue Securities LLC bought a new position in shares of Vericel in the first quarter worth about $262,000. Congress Asset Management Co. MA lifted its position in shares of Vericel by 509.1% during the 1st quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock worth $43,514,000 after purchasing an additional 699,147 shares during the last quarter. Finally, MCF Advisors LLC boosted its stake in Vericel by 86.1% during the 1st quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 223 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.